Abstract
Recombinant immunotherapeutic fusion proteins (rIFPs) were designed to target triple-negative breast cancer (TNBC). This is a heterogeneous and aggressive subset of breast cancer accounting for 15-20% of all diagnosed breast cancer cases, with women of premenopausal age and African descent inordinately predisposed. Based on previous studies, we hypothesised that the ability to bind to two identical antigens through a bivalent antibody increases the total strength of the reaction and that increasing the affinity and valency of tumour-targeting antibodies results in improved tumour uptake.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
